Deep Genomics
PrivateLast Round
Series C
Jul 28, 2021
Total Funding Raised
$236.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Deep Genomics operates in Healthcare & Life Sciences and is based in Toronto. Its latest recorded funding round was a Series C round in July 2021.
Deep Genomics is a biotechnology company that operates an AI-driven platform for genetic medicine discovery, aimed at transforming drug development by utilizing AI to unravel RNA biology and identify novel therapeutic targets and mechanisms.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Foundation
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Deep Genomics Comparables
Compare Deep Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Envisagenics | 88% | |
| Inceptive | 85% | |
| Creyon Bio | 85% |
For institutional investors. Book with your work email.
Deep Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 28, 2021 | ||||
| Series B | Jan 7, 2020 | ||||
| Series A | Sep 25, 2017 | ||||
| Seed | Nov 18, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Deep Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A |
| Magnetic Ventures | Series C, Series B |
| CPP Investments | Series C |
| Horizons Ventures | Series C |
| SoftBank Investment Advisers | Series C |
| Future Ventures | Series B |
| NJF Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 54% MoM to 14.1K.
- Oct 6, 2025
Paul Sekhri appointed to the Board of Directors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 6, 2026
Deep Genomics introduces DeepRNAi, a model that predicts siRNA activity and on- and off-target effects across the transcriptome, on Nov 5th '26.
For institutional investors. Book with your work email.
Deep Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Deep Genomics's valuation, stock price, and market status.
Is Deep Genomics a public or private company?
Deep Genomics is a private company.
What is the current stock price of Deep Genomics?
Deep Genomics is a private company, so its shares have no public market price. Caplight tracks Deep Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Deep Genomics worth (valuation)?
Valuation information for Deep Genomics is not publicly available.
Can I buy Deep Genomics stock?
Deep Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Deep Genomics's last funding round?
Deep Genomics's most recent funding round was Series C on July 28, 2021.
Who are the main investors in Deep Genomics?
Key investors in Deep Genomics include Andreessen Horowitz, SoftBank Investment Advisers, Future Ventures, Khosla Ventures, SoftBank Group.
Will Deep Genomics IPO soon?
No public IPO plans have been announced for Deep Genomics.
How can I track Deep Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Deep Genomics's shares on secondary markets.